Retention rates of tumor necrosis factor blockers in daily practice in 770 rheumatic patients

Journal of Rheumatology

Volumn 33, Issue 12, 2006, Pages 2433-2439

  Duclos, Muriel ^b   Gossec, Laure ^b   Ruyssen Witrand, Adeline ^b   Salliot, Carine ^b   Luc, Mathieu ^b   Guignard, Sandra ^b   Dougados, Maxime ^a  

^a René Descartes University ^*  (France)

^b NONE

Author keywords

Adalimumab; Etanercept; Infliximab; Retention rates

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR ANTIBODY;

ADULT; ARTICLE; DISEASE ACTIVITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SPONDYLOARTHROPATHY; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL PROTOCOLS; CLINICAL TRIALS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOGLOBULIN G; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MODELS, STATISTICAL; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; RHEUMATOLOGY; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33846090262     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;4:1552-63.
2. Maini R, St. Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumor necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving methotrexate: a randomised phase III trial. Lancet 1999;354:1932-9.
3. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
4. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
5. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45.
6. Maini R, Breedveld FC, Kalden JR, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004;50:1051-65.
7. Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002;359:1187-93.
8. Brandt J, Khariouzov A, Listing J, et al. Six-months results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003;48:1667-75.
9. van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis. Results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005;52:582-91.
10. Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356:385-90.
11. Antoni C, Kavanaugh A, Kirkham B, et al. The infliximab multinational psoriatic arthritis controlled trial (IMPACT): substantial efficacy on synovitis and psoriatic lesions with or without concomitant DMARD therapy. Arthritis Rheum 2005;52:1227-36.
12. Geborek P, Crnkic M, Petersson IF, Saxne T. Etanercept, infliximab and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis 2002;61:793-7.
13. Pincus T, Marcum SB, Callahan LF. Long-term drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second-line drugs and prednisone. J Rheumatol 1992;19:1885-94.
14. Flendrie M, Creemers MCW, Welsing PMJ, den Broeder AA, van Riel PLCM. Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis. Ann Rheum Dis 2003;62 Suppl II:30-3.
15. Ostergaard M, Unkerskov J, Krogh NS, Friis M, Ravn T, Petri A. Poor remission rates but long drug survival in rheumatoid arthritis patients treated with infliximab or etanercept - results from the nationwide Danish "DANBIO" database [abstract]. Ann Rheum Dis 2005;64 Suppl III:59.
16. Kristensen L, Geborek P, Saxne T. Adherence to therapy of etanercept and infliximab during first anti-TNF treatment course in rheumatoid arthritis [abstract]. Ann Rheum Dis 2005;64 Suppl III:431.
17. Van Vollenhoven R, Cullinane Carli C, Bratt J, Klareskog L. Secondary loss of efficacy woth TNF alpha antagonists [abstract]. Arthritis Rheum 2005;52 Suppl:S136.
18. Hochberg MC, Tracy JK, Hawkins-Holt M, Flores RH. Comparison of the efficacy of the tumour necrosis factor α blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis 2003;62 Suppl II:13-16.
19. Zink A, Listing JD, Kary S, et al. Treatment continuation in patients receiving biological or conventional DMARD therapy. Ann Rheum Dis 2005;64:1274-9.
20. Van Vollenhoven RF, Harju A, Bratt J, et al. Etanercept and infliximab treatment in the Stockholm TNF alpha antagonist registry: a comparison of two TNF alpha antagonists [abstract]. Arthritis Rheum 2001;44 Suppl:S79.
21. Van Vollenhoven RF, Harju A, Brannemark S, Klareskog L. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense. Ann Rheum Dis 2003;62:1195-8.
22. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81.
23. Breedveld F, Kavanaugh AF, Cohen SB, et al. Early treatment of rheumatoid arthritis with adalimumab plus methotrexate vs adalimumab alone or methotrexate alone: the PREMIER study [abstract]. American College of Rheumatology Annual Scientific Meeting, October 16-24, 2004; San Antonio, TX, USA. Abstract L5/520. [meeting abstracts on the Internet. Accessed July 25, 2006.] Available from: http://www.rheumatology.org/annual/abstracts/search.asp
24. Schrumpf M, Rodevand E, Mikkelsen K, et al. Adalimumab plus methotrexate is more effective than adalimumab alone in patients with rheumatoid arthritis (RA) - results from a longitudinal observational study [abstract]. Ann Rheum Dis 2005;64 Suppl 111:184.
25. Kvien TK, Schrumpf M, Mowinckel P, et al. Comparison of remission and EULAR good response rates in 1677 patients with rheumatoid arthritis receiving methotrexate, leflunomide or TNF-blocking agents: results from a longitudinal observational study [abstract]. Ann Rheum Dis 2005;64 Suppl III:450.
26. Kavanaugh AF, Ritchlin CT, Malaise MG, Wordsworth P, Birbara CA, Weinberg MA. Adalimumab treatment with and without methotrexate in patients with moderate to severe psoriatic arthritis: results from ADEPT [abstract]. Ann Rheum Dis 2005;64 Suppl III:325.
27. Breban M, Ravaud P, Claudepierre P, Baron G, Hudry C, Euller-Ziegler L. No superiority of infliximab + methotrexate over infliximab alone in the treatment of ankylosing spondylitis: results of a one-year randomized prospective study [abstract]. Arthritis Rheum 2004;50 Suppl:S214.
28. Heiberg M, Nordvag B, Mikkelsen K, et al. The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six month, longitudinal, observational, multicenter study. Arthritis Rheum 2005;52:2506-12.
29. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;3:315-24.
30. Amor B, Dougados M, Listrat V, et al. Are classification criteria for spondylarthropathy useful as diagnostic criteria? Rev Rhum Engl Ed 1995;62:10-5.
31. Keystone E, Kavanaugh A, Sharp J, et al. Radiographic, clinical and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy. Arthritis Rheum 2004;5:1400-11.
32. Wolfe F, Hawley DJ, Cathey MA. Termination of slow acting anti-rheumatic therapy in rheumatoid arthritis: A 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol 1990;17:994-1002.
33. Yazici Y, Sokka T, Kautiainen H, Swearingen C, Kulman I, Pincus T. Long term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely the result of laboratory abnormalities. Ann Rheum Dis 2005;64:207-11.
34. Shergy WJ, Philips RM Jr, Hunt RE, Hernandez J. Safety and efficacy of infliximab therapy after etanercept failure: a case series [abstract]. Arthritis Rheum 2001;44 Suppl:S81.
35. Brocq O, Plubel Y, Breuil V, et al. Switch etanercept-infliximab dans la polyarthrite rhumatoïde: 14 patients sur 131 traités par anti-TNF alpha. Presse Med 2002;3:1836-9.
36. Brocq O, Albert C, Roux C, Gerard D, Breuil V, Ziegler LE. Adalimumab in rheumatoid arthritis after failed infliximab and/or etanercept therapy: experience with 18 patients. Joint Bone Spine 2004;71:601-3.
37. Ang HTS, Helfgott S. Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other TNF-alpha antagonists in patients with rheumatoid arthritis. J Rheumatol 2003;30:2315-8.
38. Hansen KE, Hildebrand JP, Genovese MC, et al. The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. J Rheumatol 2004;3:1098-102.
39. Van der Bijl AE, Breedveld FC, Antoni CE, et al. Adalimumab is effective in treating patients with rheumatoid arthritis who previously failed infliximab treatment [abstract]. Ann Rheum Dis 2005;64 Suppl III:428.
40. Furst D, Yocum D, Weisman M, et al. Infliximab provides additional clinical and radiographic benefits in RA patients who have an inadequate response to etanercept [abstract]. Ann Rheum Dis 2005;64 Suppl III:427.
41. Nikas SN, Voulgari PV, Papadopoulos CG, Venetsanopoulou A, Georgiadis AN, Drosos AA. The efficacy and safety of switching from infliximab to adalimumab. A prospective controlled study [abstract]. Ann Rheum Dis 2005;64 Suppl III:422.
42. Pincus T, Sokka T. Should contemporary rheumatoid arthritis clinical trials be more like standard patient care and vice versa? Ann Rheum Dis 2004;63 Suppl II:ii32-ii39.
43. Pincus T, Stein CM. Why randomised controlled clinical trials do not depict accurately long-term outcomes in rheumatoid arthritis: some explanations and suggestions for future studies. Clin Exp Rheumatol 1997;15 Suppl 17:S27-S38.